As of November 2025, according to Laboratory Corp Of America Holdings's latest financial report, the company's current EPS (TTM) is $10.25. In 2024, the company recorded an earnings per share (EPS) of $8.89, which represents an increase compared to its EPS of $4.8 in 2023. Laboratory Corp Of America Holdings's earnings per share for the quarterly report ending on Sep 30, 2025 was $3.14.
The annual EPS in 2024 was $8.89, an increase of 85.2% from $4.8 in 2023. For the quarter ending Sep 30, 2025, the EPS was $3.14, showing a 55.4% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of September 2025 is $10.25. In 2023, the annual EPS was $4.8, showing a decrease of 65.8% from 2022.
Laboratory Corp Of America Holdings has recorded an increase in EPS of 55.4% over the last 12 months (YoY, quarterly). Over a three-year span, the company had an average EPS growth of -28.8% per year. Laboratory Corp Of America Holdings had an average annual EPS growth rate of 1.1% over the last 5 years. When measured over a ten-year period, LH's average EPS growth rate was 4%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| DGX Quest Diagnostics Inc | 20.58 | 2.5% | -21.1% | 4.1% |
| LH Laboratory Corp Of America Holdings | 24.44 | 85.2% | -28.8% | 1.1% |
| QGEN Qiagen NV | 25.71 | -74.7% | -44.7% | N/A |
| IDXX Idexx Laboratories Inc | 56.39 | 5.9% | 7.2% | 16.7% |
| NEO Neogenomics Inc | N/A | 11.4% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.